Atazanavir (Reyataz)

Conference Coverage

The Latest

Promo Image

What's Hot in HIV Clinical Science

What are the hottest developments in HIV clinical science over the past year? Physician-researcher Adaora Adimora, M.D., M.P.H., brought us a brief tour of key highlights at the start of the IDWeek 2015 medical conference in San Diego.

By Sony Salzman
Low-Dose Boosted Atazanavir Non-Inferior to Standard Dose in LASA Study Img

Low-Dose Boosted Atazanavir Non-Inferior to Standard Dose in LASA Study

Atazanvir/ritonavir at 200/100 mg was found to be non-inferior to atazanvir/ritonavir at 300/100 mg, according to study results presented at IAS 2015.

By Polly Clayden for HIV i-Base
HIV Antiretroviral Study Highlights From IAS 2015 Img

HIV Antiretroviral Study Highlights From IAS 2015

We briefly summarize some of the most noteworthy new HIV treatment studies presented at a major research conference that took place this month.

By Myles Helfand
Promo Image

Atazanavir, Raltegravir and Darunavir Virologically Equivalent in Naive Patients but Significant Differences for Tolerability: Results From ACTG 5257

Primary results from the ACTG 5257 study shifted the assumed relative parity between three of the preferred first-line combinations in US DHHS guidelines. Raphael Landovitz from University of California Los Angeles, presented results at CROI 2014 fro...

By Simon Collins for HIV i-Base
Promo Image

Reyataz and Kidney Stones

Reyataz, one of two preferred HIV protease inhibitor (PI) medications under U.S. treatment guidelines, is associated with the risk of kidney stones and other potential renal abnormalities. According to Japanese researchers, people taking Norvir-boost...

By Jeff Berry and Enid Vazquez for Positively Aware
Promo Image

First Report: Atazanavir-Related Gallstones (Cholelithiasis)

A poster presentation included the first report of atazanavir-related gallstones.

Following two cases of gallstones in patients on atazanavir reported to the pharmacovigilence departments of two hospitals in western France, Poinsignon and colleagues...

By Simon Collins for HIV i-Base
Promo Image

Nevirapine Sports Better Lipid Profile Than Atazanavir, Study Suggests

Patients taking Boehringer Ingelheim's HIV drug Viramune have a lower risk of developing cardiovascular disease than those taking Bristol-Myers Squibb's treatment, Reyataz, according to a study released on Monday at the 5th International AIDS Society...

By Henry J. Kaiser Family Foundation
Promo Image

ATAZIP: Switching Away From Lopinavir/Ritonavir

Switching between protease inhibitors (PIs) may lead to improved dosing frequency, better management of gastrointestinal and lipid toxicity and a reduction in ritonavir (RTV, Norvir) exposure levels. The SWAN study1 was the largest study to evaluate ...

By Graeme Moyle, M.D., M.B., B.S., Dip. G.U.M.
Promo Image

Switching From Lopinavir/Ritonavir to Unboosted Atazanavir May Yield Benefits, but Verdict Remains Uncertain

STUDY SNAPSHOTDesign:Substudy of the open-label, randomized study BMS097 (SWAN) to determine the safety and efficacy of a switch from lopinavir/ritonavir to atazanavir in virologically suppressed patients.Population:153 individuals on lopinavir/riton...

By Mark Nelson, M.B.B.S.
Promo Image

Increased I50L Prevalence Found After Unboosted Atazanavir Use in PI-Treatment-Experienced Patients

Andrew Zolopa and colleagues presented the first interim analysis from the IMPACT study (BMS AI424-128),1 a study looking at the prevalence of the HIV-1 protease gene mutation I50L, known to confer antiretroviral resistance to atazanavir (ATV, Reyata...

By Mark Holodniy, M.D.